Prior Authorization Protocol ALTOPREV (lovastatin extended release), CRESTOR (rosuvastatin), LIVALO (pitavastatin), VYTORIN (ezetimibe/simvastatin)
|
|
- Mark Booker
- 7 years ago
- Views:
Transcription
1 ALTOPREV (lovastatin extended release), CRESTOR (rosuvastatin), LIVALO (pitavastatin), VYTORIN (ezetimibe/simvastatin) Coverage of drugs is first determined by the member`s pharmacy or medical benefit. Please consult with or refer to the Evidence of Coverage document. I. FDA Approved Indications: Altoprev: As an adjunctive therapy to diet to: Reduce the risk of myocardial infarction (MI), unstable angina, and/or coronary revascularization procedures in patients without symptomatic coronary heart disease (CHD), but at high risk. Slow the progression of coronary atherosclerosis in patients with CHD as part of a treatment strategy to lower total cholesterol (Total-C) and low-density lipoprotein cholesterol (LDL-C) to target levels. Reduce elevated Total-C, LDL-C, apolipoprotein B (Apo B), and triglyceride (TG) and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia (heterozygous familial and non-familial) and mixed dyslipidemia (Fredrickson types IIa and IIb,) Crestor: Primary Hyperlipidemia and Mixed Dyslipidemia: As adjunctive therapy to diet to reduce elevated Total-C, LDL-C, ApoB, non-high-density lipoprotein cholesterol (nonhdl-c), and TG and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. Heterozygous Familial Hypercholesterolemia (HeFH): As adjunctive therapy to diet to reduce Total-C, LDL-C and ApoB in children and adolescents8-17 years of age with HeFH if after an adequate trial of diet therapy the following findings are present: LDL-C >190 mg/dl or > 160 mg/dl and there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors. Hypertriglyceridemia: As adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia. Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia): As adjunctive therapy to diet for the treatment of patients with primary dysbetalipoproteinema (Type III Hyperlipoproteinemia). Homozygous Familial Hypercholesterolemia: As adjunctive therapy to other lipid-lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDL-C, Total-C, and ApoB in adult patients with homozygous familial hypercholesterolemia. Slow the Progression of Atherosclerosis: As adjunctive therapy to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels R. Gedey, P, S Spears, D. Duane, P, L Borichevskiy, P Page - 1
2 ALTOPREV (lovastatin extended release), CRESTOR (rosuvastatin), LIVALO (pitavastatin), VYTORIN (ezetimibe/simvastatin) Primary Prevention of Cardiovascular Disease: Reduce the risk of stroke, MI, and arterial revascularization procedures in individuals without clinically evident CHD but with an increased risk of cardiovascular disease based on: Age 50 years old in men and 60 years old in women High-sensitivity C-reactive protein (hscrp) 2 mg/l The presence of at least one additional cardiovascular disease risk factor such as hypertension, low HDL-C, smoking, or a family history of premature CHD. Vytorin: Primary Hyperlipidemia: Reduction of elevated Total-C, LDL-C, Apo B, TG and nonhdl- C, and to increase HDL-C in patients with primary (heterozygous familial and nonfamilial) hyperlipidemia or mixed hyperlipidemia. Homozygous Familial Hypercholesterolemia (HoFH): Reduction of elevated Total-C and LDL-C in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. Livalo: Primary Hyperlipidemia and Mixed Dyslipidemia: As an adjunctive therapy to diet to reduce elevated TC, LDL-C, Apo B, TG, and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. II. Health Net Approved Indications and Usage Guidelines: Altoprev, Livalo Failure to achieve National Cholesterol Education Program (NCEP) goals or clinically significant adverse effects to two generic formulary statins (atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin) Crestor, Vytorin Failure to achieve NCEP goals or clinically significant adverse effects to one generic formulary statin (atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin) AND For Vytorin 10/80 mg requests, the patient has been taking 80 mg of simvastatin for 12 months or longer AND For Crestor 40 mg requests, failure to achieve NCEP goals on Crestor 20 mg III. Coverage is Not Authorized For: R. Gedey, P, S Spears, D. Duane, P, L Borichevskiy, P Page - 2
3 ALTOPREV (lovastatin extended release), CRESTOR (rosuvastatin), LIVALO (pitavastatin), VYTORIN (ezetimibe/simvastatin) Crestor total daily dose exceeding 40 mg Titration to or a new start of an 80 mg daily equivalent of simvastatin Altoprev with concomitant administration of: Strong cytochrome P450 isoform 3A inhibitors (e.g., ketoconazole, itraconazole, posaconazole, voriconazole, clarithromycin, telithromycin, HIV Protease inhibitors, boceprevir, telaprevir, nefazodone) Erythromycin Vytorin with concomitant administration of: Strong cytochrome P450 isoform 3A4 (CYP3A4) inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone, and cobicistatcontaining products) Gemfibrozil, cyclosporine, or danazol. Livalo with co-administration with cyclosporine. Non-FDA approved indications, which are not listed in the Health Net Approved Indications and Usage Guidelines section, unless there is sufficient documentation of efficacy and safety in the published literature. IV. General Information: Relative LDL-lowering Efficacy of Statin and Statin-based Therapies: Crestor has been shown to reduce LDL cholesterol by 45 to 63% with doses ranging from 5 mg to 40 mg/day. In a 6-week study, Crestor 40 mg reduced LDL cholesterol by 62.6% vs. Crestor 20 mg resulted in a LDL cholesterol reduction by 57%. Crestor given at 40 mg per day causes proteinuria as high as 10 times that of other statins. Proteinuria appears to be unique to Crestor and is not a statin class effect. Simvastatin is metabolized by the cytochrome P450 isoform 3A4. Certain drugs that inhibit this metabolic pathway can raise the plasma levels of the simvastatin component of Vytorin and may increase the risk of myopathy. Gemfibrozil can cause myopathy when used alone, and the risk of myopathy and rhabdomyolysis is increased by concomitant use with simvastatin. The area under the curve (AUC) and peak concentration (Cmax) of simvastatin are increased with concomitant gemfibrozil use. Due to the increased risk of myopathy, including rhabdomyolysis, associated with the 10/80 mg dose of Vytorin, patients unable to achieve their LDL-C goal utilizing the 10/40-mg dose of Vytorin should not be titrated to the 10/80-mg dose, but should be placed on alternative LDL-C-Iowering treatment(s) that provides greater LDL-C lowering. Crestor 80 mg can cause rhabdomyolysis in rare cases. There is no significant difference in reported incidences of myopathy or rhabdomyolysis between Crestor 40 mg and the highest commercially available doses of statins in clinical trials R. Gedey, P, S Spears, D. Duane, P, L Borichevskiy, P Page - 3
4 ALTOPREV (lovastatin extended release), CRESTOR (rosuvastatin), LIVALO (pitavastatin), VYTORIN (ezetimibe/simvastatin) Liver function tests are recommended before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (e.g. semiannually) thereafter. Crestor is contraindicated in patients with active liver disease or with unexplained persistent elevations of serum transaminases Pravastatin is FDA approved for pediatric patients 8 to 13 years up to 20 mg per day and 14 to 18 years up to 40 mg per day; simvastatin is FDA approved for pediatric patients 10 to 17 years of age up to 40 mg per day; lovastatin is FDA approved for pediatric patients 10 to 17 years of age up to 40 mg per day;and atorvastatin is FDA approved for pediatric patients 10 to 17 years of age up to 20 mg per day. Doses of Livalo greater than 4 mg once daily were associated with an increased risk for severe myopathy in pre-marketing clinical studies. Do not exceed 4 mg once daily dosing of Livalo. Cyclosporine is a known inhibitor of organic anion transporting polypeptide (OATP). Livalo is taken up into human hepatocytes mainly by OATP1B1. Cyclosporine may theoretically inhibit the uptake of Livalo into hepatocytes resulting in increased serum concentrations of Livalo with a 4.5 and 6.6 fold increase in Livalo AUC and Cmax, respectively. The risk of myopathy and rhabdomyolysis is increased by high levels of statin activity in plasma. Simvastatin and lovastatin is metabolized by the cytochrome P450 isoform 3A4. Certain drugs that inhibit this metabolic pathway can raise the plasma levels of simvastatin and may increase the risk of myopathy. V. Therapeutic Alternatives: Drug Dosing Regimen Dose Limit/Maximum Dose atorvastatin (Lipitor ) mg PO QD 80 mg/day (20 mg/day for pediatrics 10 to 17 years) simvastatin (Zocor ) 5-80 mg PO QD 80 mg/day (40 mg/day for pediatrics 10 to 17 lovastatin (Mevacor ) pravastatin (Pravachol ) *Requires Prior Authorization mg PO QD mg PO QD Pediatrics: mg PO QD years) 80 mg/day (40 mg/day for pediatrics 10 to 17 years) 80 mg/day Pediatrics: Age 8 to 13 years: 20 mg/day Age 14 to 18 years: 40 mg/day VI. Recommended Dosing Regimen and Authorization Limit: R. Gedey, P, S Spears, D. Duane, P, L Borichevskiy, P Page - 4
5 ALTOPREV (lovastatin extended release), CRESTOR (rosuvastatin), LIVALO (pitavastatin), VYTORIN (ezetimibe/simvastatin) Drug Dosing Regimen Authorization Limit Altoprev mg PO QD Length of benefit 5-40 mg PO QD Crestor In pediatric patients 10 to 17 years the usual dose range is 5-20 mg PO QD; Length of benefit doses greater than 20 mg have not been studied in this population Livalo 1-4 mg PO QD Length of Benefit 10/10-10/40 mg PO QD Use of the 10/80 mg dose of Vytorin Vytorin should be restricted to patients who have been taking Vytorin 10/80 mg for 12 Length of benefit months or more without evidence of muscle toxicity VII. VIII. Product Availability: Altoprev: 20 mg, 40 mg, 60 mg extended release tablet Crestor: 5 mg, 10 mg, 20 mg, 40 mg tablet Vytorin: 10/10 mg, 10/20 mg, 10/40 mg, 10/80 mg tablet Livalo: 1 mg, 2 mg, 4 mg tablet References: 1. Altoprev [Prescribing Information]. Atlanta, GA: Shionogi Pharma; April Crestor [Prescribing Information]. Wilmington, DE: AstraZeneca; November Vytorin [Prescribing Information]. North Wales, PA: Merck Sharp & Dohme; March Livalo. [Prescribing information] Kowa Pharmaceuticals. October Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. May 16, 2001;285(19): Micromedex Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically. Accessed: January 12, Clinical Pharmacology Web site. Available at: Accessed January 12, Crestor. American Hospital Formulary Service Drug Information. Available at: 9. Vytorin. American Hospital Formulary Service Drug Information. Available at: 10. Livalo. American Hospital Formulary Service Drug Information. Available at: R. Gedey, P, S Spears, D. Duane, P, L Borichevskiy, P Page - 5
6 ALTOPREV (lovastatin extended release), CRESTOR (rosuvastatin), LIVALO (pitavastatin), VYTORIN (ezetimibe/simvastatin) 11. Altoprev. American Hospital Formulary Service Drug Information. Available at: The material provided to you are guidelines used by this plan to authorize, modify or determine coverage for persons with similar illnesses or conditions. Specific care and treatment may vary depending on individual need and the benefits covered under your contract R. Gedey, P, S Spears, D. Duane, P, L Borichevskiy, P Page - 6
High Blood Cholesterol
National Cholesterol Education Program ATP III Guidelines At-A-Glance Quick Desk Reference 1 Step 1 2 Step 2 3 Step 3 Determine lipoprotein levels obtain complete lipoprotein profile after 9- to 12-hour
More informationgemfibrozil, cyclosporine, danazol Verapamil, diltiazem, Do not exceed 10 mg simvastatin dronedarone daily
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZOCOR safely and effectively. See full prescribing information for ZOCOR. ZOCOR () Tablets Initial
More informationPrimary Care Management of Women with Hyperlipidemia. Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing
Primary Care Management of Women with Hyperlipidemia Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing Objectives: Define dyslipidemia in women Discuss the investigation process leading
More informationHigh Cholesterol and Heart Disease
Evaluating statin drugs to treat: High Cholesterol and Heart Disease Comparing Effectiveness, Safety, and Price Contents 2: Our recommendations 4: Welcome 7: Who should take a statin drug? 10: Choosing
More informationStatins for Hyperlipidemia (High Cholesterol)
Statins for Hyperlipidemia (High Cholesterol) Examples of statin drugs Brand Name Mevacor Pravachol Zocor Lescol, Lescol XL Lipitor Crestor Chemical Name lovastatin pravastatin sodium simvastatin fluvastatin
More informationCardiovascular Risk and Dyslipidemia Management Clinician Guide MAY 2015
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Cardiovascular Risk and Dyslipidemia Management Clinician Guide MAY 2015 Introduction This Clinician Guide was developed to assist Primary Care physicians
More informationPRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION
Hull & East Riding Prescribing Committee PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION For guidance on Primary Prevention please see NICE guidance http://www.nice.org.uk/guidance/cg181
More informationHigh Cholesterol and Heart Disease
Evaluating statin drugs to treat: High Cholesterol and Heart Disease Comparing Effectiveness, Safety, and Price Contents Our Recommendations........................................... 3 Welcome....................................................
More informationSee 17 for PATIENT COUNSELING INFORMATION CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LIPITOR safely and effectively. See full prescribing information for LIPITOR. LIPITOR (atorvastatin
More informationAnti-Atheroscrerotic Drugs
Anti-Atheroscrerotic Drugs Masuko Ushio-Fukai, PhD, FAHA Dept. of Pharmacology University of Illinois at Chicago Anti-Atherogenic Drugs: Treatment of Hyperlipidemias Knowledge Objectives: 1) Know the mechanism
More informationPRESCRIBING INFORMATION Refer to Summary of Product Characteristics (SmPC) before Prescribing
EZETROL (ezetimibe) PRESCRIBING INFORMATION Refer to Summary of Product Characteristics (SmPC) before Prescribing Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
More informationTABLETS MEVACOR (LOVASTATIN)
TABLETS MEVACOR (LOVASTATIN) DESCRIPTION MEVACOR (Lovastatin) is a cholesterol lowering agent isolated from a strain of Aspergillus terreus. After oral ingestion, lovastatin, which is an inactive lactone,
More informationJNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates. January 30, 2014
JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates January 30, 2014 GOALS Review key recommendations from recently published guidelines on blood pressure and cholesterol management Discuss
More informationYour healthcare provider has ordered a Boston Heart Cardiac Risk Assessment
Your healthcare provider has ordered a Boston Heart Cardiac Risk Assessment What does that mean for you? Your healthcare provider has determined that you may be at risk for cardiovascular disease (CVD).
More informationPatient Information VYTORIN (VI-tor-in) (ezetimibe and simvastatin) Tablets
Patient Information VYTORIN (VI-tor-in) (ezetimibe and simvastatin) Tablets Read this Patient Information carefully before you start taking VYTORIN and each time you get a refill. There may be new information.
More informationTHE THIRD REPORT OF THE EXpert
SPECIAL COMMUNICATION Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
More informationCholesterol and Triglycerides What You Should Know
Cholesterol and Triglycerides What You Should Know Michael T. McDermott MD Professor of Medicine Endocrinology Practice Director Division of Endocrinology, Metabolism and Diabetes University of Colorado
More informationROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE
ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE I- BACKGROUND: Coronary artery disease and stoke are the major killers in the United States.
More informationTherapeutic Class Overview HMG CoA Reductase Inhibitors
Therapeutic Class Overview HMG CoA Reductase Inhibitors Therapeutic Class Overview/Summary: The hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors (statins) work by inhibiting HMG CoA reductase,
More informationJournal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators
Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University
More informationWelchol (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
More informationReference ID: 3539133
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CRESTOR safely and effectively. See full prescribing information for CRESTOR. CRESTOR (rosuvastatin
More informationAssociate Professor Patrick Kay Interventional cardiologist Middlemore, Auckland and Mercy Hospitals Auckland
Associate Professor Patrick Kay Interventional cardiologist Middlemore, Auckland and Mercy Hospitals Auckland 14:00-14:55 WS #45: New Therapies for Lipid Management 15:05-16:00 WS #57: New Therapies for
More informationDrug Class Review on HMG-CoA Reductase Inhibitors (Statins)
Drug Class Review on HMG-CoA Reductase Inhibitors (Statins) Final Report September 2005 The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
2.0 Synopsis AbbVie Inc. Name of Study Drug: Trilipix (ABT-335) Name of Active Ingredient: choline salt of fenofibric acid Individual Study Table Referring to Part of Dossier: Volume: Page: (For National
More information2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk Lynne T Braun, PhD, CNP, FAHA, FAAN Professor of Nursing, Nurse Practitioner Rush University Medical Center 2
More informationOmega-3 Fatty Acid Products
Omega-3 Fatty Acid Products Policy Number: 5.01.563 Last Review: 7/2016 Origination: 6/2014 Next Review: 7/2017 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for the
More informationCardiology Medications New Drugs, New Guidelines
Cardiology Medications New Drugs, New Guidelines Ken Kester, PharmD, JD Pharmacy Team Leader Nebraska Heart Hospital August 4, 2014 Cardiology Medications Objectives The attendee will understand Indications,
More informationSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling Revised: 07/2014
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CRESTOR safely and effectively. See full prescribing information for CRESTOR. CRESTOR (rosuvastatin
More informationLipid Management in Diabetic Patients (June 2014 version)
(June 2014 version) Background Accelerated atherosclerosis is multifactorial and begins years/decades prior to the diagnosis of type 2 diabetes: Risk for atherosclerotic events is two to four-fold greater
More informationBMC Med 7/19/2007; Simvastatin linked to reduced incidence of dementia, Parkinson s disease.
March 3, 2012 BD Response to FDA statement regarding Statins The Food and Drug Administration announced on Tuesday (February 28, 2012) the changes to the safety information on the labels of statins regarding
More informationData Sheet: AURO-SIMVASTATIN (Simvastatin tablets 5 mg, 10 mg, 20 mg, 40 mg & 80 mg) Ver 2.1. Name of Medicine
Name of Medicine AURO-SIMVASTATIN 5 (5 mg simvastatin tablets) AURO-SIMVASTATIN 10 (10 mg simvastatin tablets) AURO-SIMVASTATIN 20 (20 mg simvastatin tablets) AURO-SIMVASTATIN 40 (40 mg simvastatin tablets)
More informationEducation. Panel. Triglycerides & HDL-C
Triglycerides & HDL-C Thomas Dayspring, MD, ACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry of New Jersey Attending in Medicine: St Joseph s s Hospital, Paterson, NJ Certified
More informationMANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING
More informationDISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
More informationREYNOLDS QUESTION OF THE MONTH
Arizona Geriatrics Society Vol. 15 No.1 REYNOLDS QUESTION OF THE MONTH Prescribing Statins for Older Adults Is one statin superior to the others for use in the elderly? Do older adults have a higher incidence
More informationCardiology Medications New Drugs, New Guidelines
Cardiology Medications New Drugs, New Guidelines Ken Kester, PharmD, JD Pharmacy Team Leader Nebraska Heart Hospital August 4, 2014 CARDIOLOGY MEDICATIONS Objectives The attendee will understand Indications,
More informationManagement of Lipids in 2015: Just Give them a Statin?
Management of Lipids in 2015: Just Give them a Statin? James H. Stein, M.D. Division of Cardiovascular Medicine University of Wisconsin School of Medicine and Public Health Stone NJ, et al. Circulation
More informationLipid-lowering: Can ezetimibe help close the treatment gap?
REVIEW CME CREDIT RYAN C. NEAL, MD* Assistant Professor of Medicine, Baylor College of Medicine, Houston, Texas PETER H. JONES, MD Associate Professor of Medicine, Baylor College of Medicine, Houston,
More informationNEW GUIDELINES FOR CHOLESTEROL MANAGEMENT: WHAT HAS CHANGED? LAUREN HYNICKA, PHARMD, BCPS MOHAMED SARG, PHARMD, BCPS
NEW GUIDELINES FOR CHOLESTEROL MANAGEMENT: WHAT HAS CHANGED? LAUREN HYNICKA, PHARMD, BCPS MOHAMED SARG, PHARMD, BCPS NEW GUIDELINES FOR CHOLESTEROL MANAGEMENT: WHAT HAS CHANGED? ACTIVITY DESCRIPTION Cholesterol
More informationWhat is high cholesterol?
Statin medicines This brochure gives you information on high cholesterol and the medicines most commonly used to manage it. You ll learn how these medicines compare and get important information about
More informationSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 08/2013
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZETIA safely and effectively. See full prescribing information for ZETIA. ZETIA (ezetimibe) Tablets
More informationCardiovascular Risk in Diabetes
Cardiovascular Risk in Diabetes Lipids Hypercholesterolaemia is an important reversible risk factor for cardiovascular disease and should be tackled aggressively in all diabetic patients. In Type 1 patients,
More informationLIVER FUNCTION TESTS AND STATINS
LIVER FUNCTION TESTS AND STATINS Philippe J. Zamor and Mark W. Russo Current Opinion in Cardiology 2011,26:338 341 SUMMARY Purpose of review: To discuss recent data on statins in patients with elevated
More informationRx Updates New Guidelines, New Medications What You Need to Know
Rx Updates New Guidelines, New Medications What You Need to Know Maria Pruchnicki, PharmD, BCPS, BCACP, CLS Associate Professor of Clinical Pharmacy OSU College of Pharmacy Background scope and impact
More informationStatin Template Guidance Use of statins in primary and secondary prevention of vascular disease Endorsed by ABHB MTC for use in Gwent (October 2012)
Statin Template Guidance Use of statins in primary and secondary prevention of vascular disease Endorsed by ABHB MTC for use in Gwent (October 2012) Notes relating to this guidance This guidance serves
More informationStatins and Risk for Diabetes Mellitus. Background
Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration
More information10/11/2014. Laura C. Halder, Pharm.D. Postgraduate Year Two Pharmacy Resident Cardiology Abbott Northwestern Hospital Allina Health October 30, 2014
Laura C. Halder, Pharm.D. Postgraduate Year Two Pharmacy Resident Cardiology Abbott Northwestern Hospital Allina Health October 30, 2014 1 1. List two major changes to the 2013 cholesterol treatment guidelines.
More informationORIGINAL INVESTIGATION. Screening for Statin-Related Toxicity. The Yield of Transaminase and Creatine Kinase Measurements in a Primary Care Setting
ORIGINAL INVESTIGATION Screening for Statin-Related Toxicity The Yield of Transaminase and Creatine Kinase Measurements in a Primary Care Setting C. Christopher Smith, MD; Lana I. Bernstein, MD; Roger
More informationEvaluation of Non-HDL-Cholesterol/HDL-cholesterol ratio as a predictor of coronary artery disease
Journal homepage: http://www.journalijar.com INTERNATIONAL JOURNAL OF ADVANCED RESEARCH RESEARCH ARTICLE Evaluation of Non-HDL-Cholesterol/HDL-cholesterol ratio as a predictor of coronary artery disease
More informationEvidence for Caution: Women and statin use
Evidence for Caution: Women and statin use By Harriet Rosenberg Danielle Allard Women and Health Protection June 2007 Permission to duplicate is granted provided credit is given and the materials are made
More informationMEDICATION GUIDE JUXTAPID (JUKS-tuh-pid) (lomitapide) capsules
MEDICATION GUIDE JUXTAPID (JUKS-tuh-pid) (lomitapide) capsules Read this Medication Guide before your treatment. What is the most important information I should know about JUXTAPID? JUXTAPID is available
More informationScreening and Management of Lipids
Guidelines for Clinical Care Ambulatory Lipid Therapy Guideline Team Team Leader Audrey L Fan, MD General Medicine Team Members Jill N Fenske, MD Family Medicine R Van Harrison, PhD Medical Education Elizabeth
More informationMY TYPE 2 DIABETES NUMBERS
BLOOD SUGAR MANAGEMENT GUIDE MY TYPE 2 DIABETES NUMBERS Understanding and Tracking the ABCs of Type 2 Diabetes 1 BLOOD MY TYPE SUGAR 2 DIABETES MANAGEMENT ABC NUMBERS GUIDE When you have type 2 diabetes,
More informationPotential Savings from Generic Drugs in Upstate New York
T H E F A C T S A B O U T Potential Savings from Generic Drugs in Upstate New York $880 Million in Potential Savings for Upstate New York Counties Finger Lakes Region $141 million Western New York Region
More informationCardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011
Cardiovascular disease physiology Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011 Content Introduction The number 1 killer in America Some statistics Recommendations The disease process
More informationRECENT MAJOR CHANGES DRUG INTERACTIONS
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SIMCOR safely and effectively. See full prescribing information for SIMCOR. SIMCOR (niacin extended-release/)
More information2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation,
More informationMany asymptomatic individuals
Facts, myths and misconceptions about LDL-C and HDL-C By Michael B. Clearfield, DO Many asymptomatic individuals will succumb to cardiovascular disease (CVD), which is the leading cause of death and loss
More informationHow To Treat Dyslipidemia
An International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia Introduction Executive Summary The International Atherosclerosis Society (IAS) here updates
More informationMetabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007
Metabolic Syndrome Overview: Easy Living, Bitter Harvest Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Evolution of Metabolic Syndrome 1923: Kylin describes clustering
More informationPotential Clinical and Economic Impact of Statin Formulary Management
Potential Clinical and Economic Impact of Statin Formulary Management Karol E. Watson, MD Summary The evidence is clear that aggressive management of cardiac risk factors is beneficial and generally safe
More informationADD in Adults? When is it
Focus on CME at Queen s University McMaster Queen s University When is it ADD in Adults? By Nick Kates, MB, BS, FRCPC In this article: 1. How can ADD present in adults? 2. What are the symptoms of ADD?
More informationKDIGO CLINICAL PRACTICE GUIDELINE FOR LIPID MANAGEMENT IN CHRONIC KIDNEY DISEASE. Supplemental Tables November 2013
KDIGO CLINICAL PRACTICE GUIDELINE FOR LIPID MANAGEMENT IN CHRONIC KIDNEY DISEASE Supplemental Tables November 2013 Suppl Table 1: Summary table of RCT examining the effect of exercise in CKD 5HD patients
More informationReference ID: 3209595
--------------------------------CONTRAINDICATIONS------------------------------- Hypersensitivity to any component of this medication. (4.1, 6.2, 11) Active liver disease or unexplained, persistent elevations
More informationIR Conference Call on PCSK9
IR Conference Call on PCSK9 SAR236553/REGN727 PCSK9 Antibody for Hypercholesterolemia Phase 3 ODYSSEY Program Underway November 5, 2012 1 Safe Harbor Statement This presentation contains forward-looking
More informationPL 11311/0398-401 UKPAR TABLE OF CONTENTS. Lay summary Page 2. Scientific discussion Page 3. Steps taken for assessment Page 9
Simvastatin 10 mg film-coated tablets Simvastatin 20 mg film-coated tablets Simvastatin 40 mg film-coated tablets Simvastatin 80 mg film-coated tablets PL 11311/0398-401 UKPAR TABLE OF CONTENTS Lay summary
More informationDrug-Drug Interactions
Slide 1 Drug-Drug Interactions David Back University of Liverpool UK David Back University of Liverpool C-Hep Berlin October 2012 Interactions with the new HepC drugs are challenging! Slide 2 Number of
More informationCurriculum Vitae. James C. Thomas, M.D. Medical University of South Carolina. University of Georgia, Athens, Georgia, 1966. Degree B.S.
Curriculum Vitae James C. Thomas, M.D. Present Position Other addresses Clinical/research Associate Professor, Department of Internal Medicine, MUSC Cholesterol Center, 135 Rutledge Ave., Room 1249, Charleston,
More informationNew Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine
New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine Disclosures & Relevant Relationships I have nothing to disclose No financial conflicts Editor,
More informationEvidence-Based Secondary Stroke Prevention and Adherence to Guidelines
Evidence-Based Secondary Stroke Prevention and Adherence to Guidelines Mitchell S.V. Elkind, MD, MS Associate Professor of Neurology Columbia University New York, NY Presenter Disclosure Information Mitchell
More informationUnderstanding Pharmacokinetic Variability and Managing Drug Interactions
Understanding Pharmacokinetic Variability and Managing Drug Interactions Courtney V. Fletcher, Pharm.D. Dean, College of Pharmacy Professor, Department of Pharmacy Practice and Division of Infectious Diseases
More informationHalf-dose ezetimibe add-on to statin therapy is effective in improving resistant hyperlipidaemia in Asian patients with ischaemic heart disease
Original Article Singapore Med J 2011; 52(6) : 400 Half-dose ezetimibe add-on to statin therapy is effective in improving resistant hyperlipidaemia in Asian patients with ischaemic heart disease Chong
More informationAACE Guidelines. Copyright 2012 AACE
AACE Guidelines Paul S. Jellinger, MD, MACE; Donald A. Smith, MD, FACE; Adi E. Mehta, MD, FRCP(C), FACE; Om Ganda, MD, FACE; Yehuda Handelsman, MD, FACP, FACE; Helena W. Rodbard, MD, FACP, MACE; Mark D.
More informationHôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires
Hôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires Prof. J. Philippe Effect of estrogens on glucose metabolism : Fasting Glucose, HbA1c and C-Peptide
More informationSecondary Prevention and Rehabilitation
Secondary Prevention and Rehabilitation Effectiveness of a planned strategy using cardiac rehabilitation nurses for the management of dyslipidemia in patients with coronary artery disease Manohara P. J.
More information4/4/2013. Mike Rizo, Pharm D, MBA, ABAAHP THE PHARMACIST OF THE FUTURE? METABOLIC SYNDROME AN INTEGRATIVE APPROACH
METABOLIC SYNDROME AN INTEGRATIVE APPROACH AN OPPORTUNITY FOR PHARMACISTS TO MAKE A DIFFERENCE Mike Rizo, Pharm D, MBA, ABAAHP THE EVOLUTION OF THE PHARMACIST 1920s 1960s 2000s THE PHARMACIST OF THE FUTURE?
More informationEvidence for Statins in
Evidence for Statins in Secondary & Primary Prevention Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine (Cardiology) Co Director, Prevention Intervention Center University
More informationHYPERTENSION ASSOCIATED WITH RENAL DISEASES
RENAL DISEASE v Patients with renal insufficiency should be encouraged to reduce dietary salt and protein intake. v Target blood pressure is less than 135-130/85 mmhg. If patients have urinary protein
More informationMain Effect of Screening for Coronary Artery Disease Using CT
Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,
More informationTreatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).
Complete Summary GUIDELINE TITLE (1)Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment
More informationLipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines
Lipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines Amit Sachdeva, MD, a Christopher P. Cannon, MD, b Prakash C. Deedwania,
More informationFamilial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients
Journal of Clinical Lipidology (2011) 5, 133 140 Executive Summary Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients Clinical guidance from the National
More informationAtherosclerotic Cardiovascular Disease (ASCVD) Secondary Prevention Guideline 1
Atherosclerotic Cardiovascular Disease (ASCVD) Secondary Prevention Guideline Major Changes as of January 2016... 2 Preface... 2 Definitions... 3 Target Population... 3 Goals of ASCVD Secondary Prevention...
More informationManaging potential drug-drug interactions to achieve success in HCV triple therapy. David Back University of Liverpool
Managing potential drug-drug interactions to achieve success in HCV triple therapy David Back University of Liverpool Understanding the metabolic pathways of DAAs Drug CYP 3A4 P-gp Telaprevir Boceprevir
More informationThe incidence of true liver injury
Considerations for Safe Use of Statins: Liver Enzyme Abnormalities and Muscle Toxicity R. CLARK GILLETT, JR., MD, and ANGELICA NORRELL, PharmD, Columbus Regional Healthcare System, The Medical Center,
More informationMICHAEL GEE, PharmD; NOELLE K. HASSON, PharmD; TERRI HAHN, BSPharm; and RUSSELL RYONO, PharmD
ORIGINAL RESEARCH Effects of a Tablet-Splitting Program in Patients Taking HMG-CoA Reductase Inhibitors: Analysis of Clinical Effects, Patient Satisfaction, Compliance, and Cost Avoidance MICHAEL GEE,
More informationMaking Sense of the New Statin guidelines. They are more than just lowering your cholesterol!
Making Sense of the New Statin guidelines They are more than just lowering your cholesterol! No Disclosures Margaret (Peg) O Donnell DNPs, FNP, ANP B-C, FAANP Senior Nurse Practitioner South Nassau Communities
More informationPCSK9 Inhibitors for Treatment of High Cholesterol: Effectiveness, Value, and Value- Based Price Benchmarks Draft Report
PCSK9 Inhibitors for Treatment of High Cholesterol: Effectiveness, Value, and Value- Based Price Benchmarks Draft Report A Technology Assessment Draft Report September 8, 2015 Completed by: Institute for
More informationWill The Coronary Calcium Score Affect the Decision To Treat With Statins?
Will The Coronary Calcium Score Affect the Decision To Treat With Statins? Amresh Raina M.D. Division of Cardiology University of Pennsylvania Disclosures No financial relationships relevant to this presentation
More informationYour Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007
Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007 The cardiometabolic risk syndrome is increasingly recognized
More informationDiabetes Mellitus Type 2
Diabetes Mellitus Type 2 What is it? Diabetes is a common health problem in the U.S. and the world. In diabetes, the body does not use the food it digests well. It is hard for the body to use carbohydrates
More informationCardiovascular Effects of Drugs to Treat Diabetes
Cardiovascular Effects of Drugs to Treat Diabetes Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies Clinical Trials:
More informationLIPID PANEL CHOLESTEROL LIPOPROTEIN, ELECTROPHORETIC SEPARATION LIPOPROTEIN, DIRECT MEASUREMENT (HDL) LDL DIRECT TRIGLYCERIDES
Test Code Test Name CPT CHOL Cholesterol, Serum 82465 HDL HDL, (High Density Lipoprotein) 83718 TRIG Triglycerides, Serum 84478 FTRIG Triglycerides (Fluid) 84478 LIPID Lipid Panel 80061 LDL LDL (Low Density
More informationADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,
More informationDrug-Drug Interactions in the Treatment of Hepatitis C
Drug-Drug Interactions in the Treatment of Hepatitis C Jennifer J. Kiser, PharmD University of Colorado Denver Department of Pharmaceutical Sciences May 11, 2013 Disclosures Jennifer Kiser receives or
More informationInitiation and Adjustment of Insulin Regimens
Start with bedtime intermediateacting insulin or bedtime or morning long-acting insulin (can initiate with 10 units or 0.2 units per kg) Initiation and Adjustment of Insulin Regimens Insulin regimens should
More informationNCD for Lipids Testing
Applicable CPT Code(s): NCD for Lipids Testing 80061 Lipid panel 82465 Cholesterol, serum or whole blood, total 83700 Lipoprotein, blood; electrophoretic separation and quantitation 83701 Lipoprotein blood;
More informationPrescription Cholesterol-lowering Medication Use in Adults Aged 40 and Over: United States, 2003 2012
NCHS Data Brief No. 77 December 4 Prescription Cholesterol-lowering Medication Use in Adults Aged 4 and Over: United States, 3 2 Qiuping Gu, M.D., Ph.D.; Ryne Paulose-Ram, Ph.D., M.A.; Vicki L. Burt, Sc.M.,
More informationReview Article. Indian J Med Res 138, October 2013, pp 461-491. Enas A. Enas, Arun Kuruvila, Pravien Khanna, C.S. Pitchumoni * & Viswanathan Mohan **
Review Article Indian J Med Res 138, October 2013, pp 461-491 Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians A population with the highest risk of
More information